Retinopathy Drug in the Works

By: Daniel Trecroci

On April 20, 2006, Eli Lilly & Co. told Diabetes Health that the U.S. Food and Drug Administration has granted priority review status for Arxxant, its potential “first-in-class treatment” for diabetic retinopathy.

Diabetic retinopathy is a result of damage to the small blood vessels in the back of the eye caused by diabetes. According to Eli Lilly, about 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy, which can lead to vision loss and blindness.

“Currently, there are no approved prescription products to treat diabetic retinopathy, says Eli Lilly. “Arxxant has the potential to represent a significant improvement in the treatment of diabetic retinopathy.”



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.